{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:35Z","timestamp":1781650835185,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pharmacoeconomic evaluation of clinical pharmacy services (CPS) aims to assess the contribution of clinical pharmacists (CP) to optimize the medication process by interventions while simultaneously saving costs. The objective of this study was to provide a valuable contribution by calculating the pharmacoeconomic benefit per full-time equivalent (FTE) comparing costs of avoided adverse drug events (ADE) with CP wage costs in a German tertiary care centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CPs recorded their interventions according to an internal documentation tool, and an expert panel evaluated the likelihood that these interventions would have averted an ADE. The internal cost-avoidance analysis involved determining the total amount of ADE excess costs that could potentially be avoided in 2021. This was achieved by multiplying the median probability of an ADE occurring, as evaluated by an expert panel, by the inflation-adjusted ADE excess costs. These factors, in combination with CP wage costs contributed to the calculation of the pharmacoeconomic benefit. FTEs were used to improve comparability. Deterministic sensitivity analysis was conducted for relevant parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Some 221 out of 3,562 recorded active interventions were analysed. The major interventions made by CPs were medication stops or dosage changes, representing more than 50% of all CPS provided in 2021. To sum up, the findings demonstrated that interventions preventing ADEs are beneficial. A pharmacoeconomic benefit of \u20ac13,467 per FTE was calculated. The sensitivity analysis revealed further savings potential, as our model was based on rather conservative assumptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study has demonstrated pharmacoeconomic benefits of CP interventions. The necessity of integrating CPs into routine care to improve patient care quality while increasing economic efficiency has been proven. Future studies should investigate the long-term effects of these interventions and their implementation in other healthcare facilities to determine the full potential of CPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-14527-w","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:35:46Z","timestamp":1777124146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The economic impact of clinical pharmacists in a tertiary care centre in Germany: pharmacoeconomic benefit calculation using cost-avoidance analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8851-2443","authenticated-orcid":false,"given":"Julia","family":"Borella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-0754","authenticated-orcid":false,"given":"Donald","family":"Ranft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4028-5774","authenticated-orcid":false,"given":"Dominik","family":"Rottenkolber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-3362","authenticated-orcid":false,"given":"Nikolaus","family":"von Dercks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6655","authenticated-orcid":false,"given":"Thilo","family":"Bertsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4321-1553","authenticated-orcid":false,"given":"Yvonne","family":"Remane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"14527_CR1","doi-asserted-by":"crossref","unstructured":"Ibanez-Garcia S, Rodriguez-Gonzalez C, Martin-Barbero M, Sanjurjo-Saez M, Herranz-Alonso A. Adding value through pharmacy validation: a safety and cost perspective. J Eval Clin Pract. 2016:253\u201360.","DOI":"10.1111\/jep.12466"},{"key":"14527_CR2","doi-asserted-by":"crossref","unstructured":"Kopp B, Mrsan M, Erstad B, Duby J. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007:2483\u20137.","DOI":"10.2146\/ajhp060674"},{"key":"14527_CR3","doi-asserted-by":"crossref","unstructured":"Neville H, Chevalier B, Daley C, Nodwell L, Harding C, Hiltz A. Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. Int J Pharm Pract. 2014:216\u201322.","DOI":"10.1111\/ijpp.12058"},{"key":"14527_CR4","doi-asserted-by":"crossref","unstructured":"Geer M, Koul P, Tanks S, Shah M. Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016:323\u201334.","DOI":"10.1016\/j.vascn.2016.04.011"},{"key":"14527_CR5","doi-asserted-by":"crossref","unstructured":"Formica D, Sultana J, Cutroneo P, Lucchesi S, Angelica R, Crisafulli S. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Exp Opin Drug Saf. 2018:681\u201395.","DOI":"10.1080\/14740338.2018.1491547"},{"issue":"33","key":"14527_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2165\/11536800-000000000-00000","volume":"10","author":"L Hoonhout","year":"2010","unstructured":"Hoonhout L, Bruijne Md, Wagner C, van der Asscheman H, van Tulder M. Nature, occurrence and consequences of medication-related adverse drug events during hospitalization. Drug Saf. 2010;10(33):853\u201364.","journal-title":"Drug Saf"},{"key":"14527_CR7","doi-asserted-by":"crossref","unstructured":"Jourdan J, Muzard A, Goyer I, Ollivier Y, Oulkhouir Y, Henri P, et al. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital. Int J Clin Pharm. 2018:1474\u201381.","DOI":"10.1007\/s11096-018-0733-6"},{"key":"14527_CR8","doi-asserted-by":"crossref","unstructured":"Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German hospitals\u2013 a microcosting study. Value Health. 2012:868\u201375.","DOI":"10.1016\/j.jval.2012.05.007"},{"key":"14527_CR9","doi-asserted-by":"crossref","unstructured":"Nesbit T, Shermock K, Bobek M, Capozzi D, Flores P, Leonard M et al. Implementation and pharmacoeconomic analysis of clinical staff pharmacist practice model. Amercian J Health Syst Pharm. 2001:784\u201390.","DOI":"10.1093\/ajhp\/58.9.784"},{"key":"14527_CR10","doi-asserted-by":"crossref","unstructured":"Patanwala A, Narayan S, Haas C, Abraham I, Sanders A, Erstad B. Proposed guidance on cost-avoidance studies in pharmacy practice. Am J Health Syst Pharm. 2021:1559\u201367.","DOI":"10.1093\/ajhp\/zxab211"},{"key":"14527_CR11","unstructured":"Deutsche Aktuarvereinigung e.V. Welche Auswirkungen hat die medizinische Inflation auf die private Kranken- und Pflegeversicherung? Aktuar Aktuell. 2019:8\u20139."},{"key":"#cr-split#-14527_CR12.1","unstructured":"Statistisches Bundesamt (Destatis). Zeitreihe 61111-0001: Verbraucherpreisindex Deutschland - Jahresdurchschnitte (Basisjahr 2020\u2009=\u2009100) 2012-2021 [Internet]. GENESIS-Online"},{"key":"#cr-split#-14527_CR12.2","unstructured":"[cited 2026 Jan 9]. Available from: https:\/\/www-genesis.destatis.de\/genesis\/online?sequenz=tabelleErgebnis&selectionname=61111-0001&startjahr=2012&endjahr=2021"},{"issue":"22","key":"14527_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12913-021-07460-7","volume":"27","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs A, Carswell C, et al. CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Serv Res. 2022;27(22):114.","journal-title":"BMC Health Serv Res"},{"key":"14527_CR14","doi-asserted-by":"crossref","unstructured":"Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Nat Res Sci Rep. 2021;(11): 883.","DOI":"10.1038\/s41598-020-80560-2"},{"key":"14527_CR15","doi-asserted-by":"crossref","unstructured":"Lee A, Boro M, Knapp K, Meier J, Korman N. Clinical an economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm. 2002:2070\u20137.","DOI":"10.1093\/ajhp\/59.21.2070"},{"key":"14527_CR16","doi-asserted-by":"crossref","unstructured":"Lampert M, Kraehenbuehl S, Hug B. Drug-related problems: evaluation of a classification system in the daily practice of a Swiss University Hospital. Pharmacy World & Science; 2008. pp. 768\u201376.","DOI":"10.1007\/s11096-008-9213-8"},{"key":"14527_CR17","unstructured":"van den Bosma B, Melief P, van Bommel J, Tann S, Hunfeld N. Pharmacist Interventions during patient rounds in two intensive care units: Clinical and financial impact. Neth J Med. 2018:115\u201324."},{"issue":"7","key":"14527_CR18","doi-asserted-by":"publisher","first-page":"e5853","DOI":"10.1002\/pds.5853","volume":"33","author":"WN Kelly","year":"2024","unstructured":"Kelly WN, Ho MJ, Smith T, Bullers K, Bates DW, Kumar A. Association of Pharmacist Interventions With Adverse Drug Events and Potential Adverse Drug Events. Pharmacoepidemiol Drug Saf. 2024;33(7):e5853. https:\/\/doi.org\/10.1002\/pds.5853.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14527_CR19","doi-asserted-by":"crossref","unstructured":"Gom\u00e9z Costas D, Ribed A, Gimenez-Manzorro A, Garutti I, Sanz F, Taldriz-Sender I, et al. Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis. Eur J Hosp Pharm. 2024:1\u20136.","DOI":"10.1136\/ejhpharm-2024-004222"},{"key":"14527_CR20","doi-asserted-by":"crossref","unstructured":"Liebing N, Ziehr B, R\u00f6ber S, Nibbe L, Oppert M, Warnke U. Stationsapotheker:innen in der Intensivmedizin: \u00f6konomische Nutzenanalyse. Medizinische Klinik Intensivmedizin und Notfallmedizin. 2024:1\u20136.","DOI":"10.1007\/s00063-023-01102-y"},{"key":"14527_CR21","doi-asserted-by":"crossref","unstructured":"Al-Qudah RA, Al-Badriyeh D, Al-Ali FM, Altawalbeh SM, Basheti IA. Cost-benefit analysis of clinical pharmacist intervention in preventing drug events in the general chronic diseases outpatients. J Eval Clin Pract. 2020;26:115\u201324.","DOI":"10.1111\/jep.13209"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14527-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:11Z","timestamp":1781649911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14527-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14527"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14527-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"610"}}